-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Phase III. Clinical Trial of China Bio-New Coronary Inactivated Vaccine III., a pharmaceutical group, has been fully launched in Egypt, Africa, and is progressing steadily.
28, Egyptian Health and Population Minister Haley came to the site of a clinical trial as a volunteer to be vaccinated.
said the public should actively participate in clinical trials of the new crown vaccine and contribute to the development of the new crown vaccine as soon as possible.
she also said that more than 40,000 people have participated in the new crown vaccine III. phase III clinical trials conducted by Chinese organisms around the world, and no serious adverse reactions have been detected.
Khaled Makhad, an adviser to Egypt's Minister of Health and Population and press spokesman, said Haley first underwent temperature monitoring outside the clinical trial building, then recorded personal data in the registration window and received a file of his participation in the clinical trial.
medical professionals briefed the Minister in detail on the basic situation of the phase III clinical trial of the new crown vaccine, followed by a medical examination and medical history inquiry, after the medical staff informed the relevant details, the Minister signed the informed consent.
after PCR testing and blood sample collection, the Minister was vaccinated in the vaccination room.
, deputy director of the Wuhan Biological Products Research Institute of Chinese Biology, participated in the event at the scene.
, Zhu Jingjin, president of the biological products division of the National Pharmaceutical Group, held talks with Minister Harley in Cairo.
Zhu Jingjin introduced to Minister Harley that in the course of fighting the new crown epidemic, China National Pharmaceutical Group china Bio took the lead in developing a new coronavirus nucleic acid molecular testing reagent for disease source screening, the first to propose recovery plasma therapy for the treatment of serious patients, the first to develop specific immunoglobulin for the treatment of patients with neo crown pneumonia, and the first to develop the world's first new coronary inactivated vaccine, making outstanding contributions to the prevention and control of the epidemic.
new coronal inactivated vaccine for Chinese organisms is currently in the United Arab Emirates, Bahrain, Egypt and other countries in an orderly manner to advance Phase III clinical trials, the sample population now covers 125 countries.
Minister Khale expressed appreciation for the anti-epidemic work of the Chinese bio-epidemic group and conveyed the concern of Egyptian Prime Minister Mustafa Madebli about the phase III clinical trial of the new crown vaccine in Cairo.
said she hopes to contribute to the common cause of mankind through sincere cooperation.
Egyptian Ministry of Health and Population Source: Egyptian Ministry of Health and Population Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mes Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.